Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$356.40 USD

356.40
364,922

+13.51 (3.94%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $357.00 +0.60 (0.17%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 31% (173 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zacks Industry Outlook Highlights Medpace, Doximity and Biodesix

by Zacks Equity Research

Medpace, Doximity and Biodesix have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy as Industry Trends Improve

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, DOCS and BDSX are set to gain the most. However, staffing shortages may disrupt the growth trend.

Here's Why You Should Invest in Centene (CNC) Stock Now

by Zacks Equity Research

Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FXH

Are Medical Stocks Lagging ACADIA Pharmaceuticals (ACAD) This Year?

by Zacks Equity Research

Here is how Acadia Pharmaceuticals (ACAD) and Medpace (MEDP) have performed compared to their sector so far this year.

Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?

by Zacks Equity Research

Sector ETF report for FXH

Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.

Is Medpace (MEDP) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

by Zacks Equity Research

National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.

Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut

by Zacks Equity Research

Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.

Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down

by Zacks Equity Research

Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.

STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down

by Zacks Equity Research

STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Cencora, Inc. (COR) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Bruker (BRKR) Q3 Earnings and Revenues Top, '23 Sales View Up

by Zacks Equity Research

Bruker (BRKR) delivers better-than-expected earnings and revenues in the third quarter of 2023.

Prestige Consumer (PBH) Q2 Revenues Top, Margins Expand

by Zacks Equity Research

Prestige Consumer's (PBH) second-quarter fiscal 2024 results benefit from a diverse brand portfolio and broad distribution.

Omnicell (OMCL) Q3 Earnings and Revenues Beat, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) third-quarter 2023 results reflect operational discipline in a weak demand environment.

Tandem Diabetes (TNDM) Posts Wider Q3 Loss, Trims '23 Sales View

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-anticipated loss in the third quarter of 2023.

Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

STERIS (STE) Set to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS' (STE) second-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.

Tirthankar Chakraborty headshot

5 Stocks Worth a Buy for Remarkable Earnings Growth

by Tirthankar Chakraborty

Invest in stocks such as Hilton Worldwide (HLT), Stride (LRN), Costco Wholesale (COST), Medpace (MEDP) and H&E Equipment Services (HEES) for superb earnings growth.

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

by Zacks Equity Research

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Hologic (HOLX) Q4 Earnings Might Rise on 7.7% Breast Health Growth

by Zacks Equity Research

Strength in Breast Health and growing Panther instrument installed base will likely benefit Hologic's (HOLX) Q4 performance.

Henry Schein (HSIC) Set to Post Q3 Earnings: What Awaits?

by Zacks Equity Research

Henry Schein's (HSIC) third-quarter 2023 results are likely to reflect the strong fundamentals of the Dental business.